Study details
Enrolling now
Effectiveness and Safety of Zavegepant in Adults Using CGRP Preventive Medications for Migraine Treatment
Mayo Clinic
NCT IDNCT06401642ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
200
Study length
about 3 years
Ages
18+
Locations
1 site in AZ
About this study
Researchers are testing whether zavegepant, a medication, can effectively treat migraine attacks in adults who are already taking medications to prevent migraines. The trial will also evaluate how well zavegepant is tolerated by participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Zavegepant
PhasePhase 4
DrugZavegepant
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low4%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
zavegepant
Endpoints
Secondary: Adverse events, Discontinuation due to adverse events, Serious adverse events
Body systems
Neurology